Xuezhikang Capsule for Type 2 Diabetes with Hyperlipemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trails

Table 1

The basic information of each study.

Study ID	Sample (T/C)	Intervention group	Control group	Course (week)	Outcome measures
Liao and Chen 2010 [7]	40/40	XZK + BGLD	Simvastatin + BGLD	8	TC, TG, HDL-C, LDL-C
Liu and Dong 2008 [8]	30/30	XZK + BGLD	Simvastatin + BGLD	8	TC, TG, HDL-C, LDL-C
Wang et al. 2005 [9]	32/30	XZK + BGLD	Pravastatin + BGLD	8	TC, TG, HDL-C, LDL-C
	32/30	XZK + BGLD	Fenofibrate + BGLD	8	TC, TG, HDL-C, LDL-C
Lanfan and Zurong 2005 [10]	32/30	XZK + BGLD	Simvastatin + BGLD	8	TC, TG, HDL-C, LDL-C
Tong 2012 [11]	23/23	XZK + BGLD	Simvastatin + BGLD	8	TC, TG, HDL-C, LDL-C
Zhe 2012 [12]	39/39	XZK + BGLD	Atorvastatin + BGLD	12	TC, TG, HDL-C, LDL-C
Xueling 2007 [13]	30/30	XZK + BGLD	Fluvastatin + BGLD	12	TC, TG, HDL-C, LDL-C
Chen 2013 [14]	45/44	XZK + BGLD	Simvastatin + BGLD	12	TC, TG, HDL-C, LDL-C
Yang 2008 [15]	60/60	XZK + BGLD	Simvastatin + BGLD	12	TC, TG, HDL-C, LDL-C
Jianhui 2013 [16]	23/20	XZK + BGLD	Rosuvastatin + BGLD	12	TC, TG, HDL-C, LDL-C
Hui and Zhaoliang 2005 [17]	46/43	XZK + BGLD	Simvastatin + BGLD	12	TC, TG, HDL-C, LDL-C
Tang and Weng 2002 [18]	40/40	XZK + BGLD	BGLD	8	TC, TG, HDL-C
Zhang and Chen 2010 [19]	22/23	XZK + BGLD	BGLD	12	TC, TG, HDL-C, LDL-C
Yang et al. 2013 [20]	32/34	XZK + BGLD	BGLD	12	TC, TG, HDL-C, LDL-C
Tongcui and Bihui 2002 [21]	35/30	XZK + BGLD	BGLD	8	TC, TG, HDL-C, LDL-C
	35/30	XZK + BGLD	BGLD	12	TC, TG, HDL-C, LDL-C
Lin et al. 2000 [22]	48/32	XZK + BGLD	Placebo + BGLD	8	TC, TG, HDL-C, Effectiveness
Chen et al. 2000 [23]	30/30	XZK + BGLD	Placebo + BGLD	8	TC, TG, HDL-C, Effectiveness
Chen 2004 [24]	135/133	XZK + BGLD	Placebo + BGLD	12	TC, TG, HDL-C, LDL-C
Hao 2002 [25]	52/53	XZK + BGLD	Duoxikang + BGLD	8	TC, TG, HDL-C, Effectiveness